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Summary
Non-proportional hazards (NPH) have been observed in many immuno-oncology
clinical trials. Weighted log-rank tests (WLRT) with suitable weights can be used to
improve the power of detecting the difference between survival curves in the presence
of NPH. However, it is not easy to choose a proper WLRT in practice. A versatile
maxcombo test was proposed to achieve the balance of robustness and efficiency, and
has received increasing attention recently. Survival trials often warrant interim anal-
yses due to their high cost and long durations. The integration and implementation
of maxcombo tests in interim analyses often require extensive simulation studies. In
this report, we propose a simulation-free approach for group sequential designs with
the maxcombo test in survival trials. The simulation results support that the proposed
method can successfully control the type I error rate and offer excellent accuracy and
flexibility in estimating sample sizes, with light computation burden. Notably, our
method displays strong robustness towards various model misspecifications and has
been implemented in an R package for free access online.
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1 INTRODUCTION
Survival outcomes are common end-points of interest in confirmatory trials to demonstrate treatment effect in oncology. In the
presence of non-proportional hazards (NPH), which has been increasingly encountered in practice, the detection power of the
commonly used log-rank test is much lower than those under proportional hazards (PH). For instance, delayed treatment effect
was often reported in immune-directed anti-cancer therapies1,2. Unlike chemotherapy, which displays early antitumor effects
or separation between the survival curves, immunotherapy stimulates the patient’s immune system for an antitumor response,
causing delayed clinical effects3.
Weighted log-rank tests (WLRT) incorporate time-dependent weights to improve the detection power in the presence of non-
proportional hazards. Weight functions can be dependent on survival functions4 or at-risk proportions5,6. In this report, we focus
on the Fleming-Harrington class of WLRT, but one can easily extend the proposed design to other weight functions. The shape
of the Fleming-Harrington weight function can be adjusted according to the survival curves. For example, one can put more
weight on late separation for delayed treatment effect to improve the detection power. According to Schoenfeld7, the optimal
weight (with the highest power) should be proportional to the logarithm of the hazard ratio8, which is a time-dependent function
under NPH.
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Survival curves are generally unknown, and thus, the appropriate weight function cannot be decided before starting the trial.
Lee9 proposed a versatile max-combo test, which takes the maximum value of a set of different WLRT to provide a robust
detection. In other words, whether it is PH or NPH, the max-combo test gives power quite close to the optimal one in the combo
of different WLRT. A typical maxcombo test combines several WLRT, each of which is most powerful in detecting a certain
pattern of NPH or PH difference between treatment arms, and the multiple testing adjustment is conducted via a Dunnett-type
parametric method.
Interim analysis (IA) in group sequential design (GS) enables multiple looks (interims) before the end of the study. They will
allow early stops when there is sufficient evidence to discontinue the study, like the rejection of the null hypothesis, toxic effects,
and futility. Though their benefits have been extensively studied, to the best of our knowledge, group sequential designs with
max-combo tests (GS-MC) have not been systematically established. In this report, we develop a simulation-free approach to
calculate the stopping boundaries with GS-MC design. As shown in the sequel, our methods can control type I error and provide
an efficient way of computing the power and sample size with a GS-MC design.
The rest of this report is organized as follows. We introduce the designs of WLRT and the max-combo test, and extend them
to GS-MC in Section 2. We propose simulation-free approaches for GS-MC to compute boundaries for type I error control and
practical sample size in realistic scenarios in Section 3. We evaluate the proposed methods through extensive simulations with
or without violations of the model assumptions in Section 4. Some concluding remarks are provided in Section 5.
2 PROBLEM FORMULATION
2.1 Notation
Suppose there are 푛 subjects entering the study at 퐸푖, 푖 = 1,… , 푛, within the accrual period [0, 푅]. Let 푇푖 denote a univariate
event time of interest, and 퐴푖 indicate treatment assignment, e.g. using 0 for the control group and 1 for the treatment group.
Given the treatment 퐴푖 = 푎, 푎 ∈ {1, 0}, event time 푇푖 follows a survival function 푆푎(푠) = 푃 (푇푖 > 푠 ∣ 퐴푖 = 푎). To consider
censoring time 퐶푖, the observed follow-up time and event indicator are {푌푖(푡) = 푚푖푛(푇푖, 퐶푖, 푡 − 퐸푖)} and 훿푖(푡) = 퐼(푌푖(푡) = 푇푖),
where 푡 is a stopping time for tests. Alternatively, observed event times can also be written in a counting process form, i.e.,
푁푖(푡, 푠) = 퐼(푇푖 ≤ 푠, 훿푖(푡) = 1). Note that 푡 and 퐸푖 follow the chronological time scale, while 푠 in all the functions, 푇푖 and 퐶푖 are
in a follow-up time scale starting from the accrual time 퐸푖. The censoring might differ between the two treatment arms so that
the survival functions of censoring are 푆푐푎(푠) = 푃 (퐶푖 > 푠 ∣ 퐴푖 = 푎), 푎 = 0, 1.
In this report, we allow both the control and the treatment group to follow piecewise exponential distributions with a general
form:
푆푎(푠) = exp
[
−
푄∑
푞=1
휆푎푞 max
{
0,min(휖푞 − 휖푞−1, 푠 − 휖푞−1)
}]
, 푎 = 1, 0. (1)
Note that 0 = 휖0 < 휖1 < ⋯ < 휖푄 = ∞ are the splitting points where the hazard changes, and 휆푎푞 is the hazard in the interval
[휖푞−1, 휖푞), 푞 = 1,… , 푄. The flexibility of including multiple pieces enables an accurate approximation of any survival curves.
The corresponding density function is 푓푎(푠) = 푆푎(푠)∑푄푞=1 퐼(푠 ∈ [휖푞−1, 휖푞))휆푎푞 . The hazard ratios between the two treatmentarms are횯 = {휃푞 = 휆1푞∕휆0푞 , 푞 = 1,… , 푄}. The hazard ratios can describe all different changing pattern of the treatment effects,
e.g., constant hazard ratio or PH cases with 휃푞 identical for ∀푞, and delayed or increasing effects with 0 < 휃푄 < ⋯ < 휃1 ≤ 1
etc. For delayed treatment effect, a simple NPH case is given in Appendix B (B4) and (B5) with only the two-piece exponential
distribution considered: hazards are 휆11 = 휆01 = 휆 and 휃1 = 1 for [0, 휖), 휆12 = 휃2휆 and 휆02 = 휆 for [휖,∞). In this simple case,
the null hypothesis (퐻0) has 휃2 = 1 and the alternative hypothesis (퐻1) has 휃2 = 휃 with some 휃 < 1. Or more broadly speaking,
the null hypothesis 퐻0 is always 횯 = 횯0 with all elements 휃푞 = 1, and the alternative one 퐻1 could embrace any predefined
횯 = 횯1 with at least one of elements 휃푞 ≠ 1. Additionally, we assume uniform accrual and administrative right censoring
at time 휏 following the proposal of Hasegawa10 in Section 3 when developing our solutions. However, the robustness of the
proposed approaches towards the assumption violations can be seen in Section 4, and easy extensions on the proposed method
could be incorporated to accommodate more complicated scenarios in future studies. For example, one could implement the
method from Luo et al11 for all types of piece-wise exponential distributions under various censoring and accrual processes.
2.2 Weighted log-rank test
Suppose the treatment-specific at-risk proportions are 푅푎(푡, 푠) = 1푛
∑푛
푖=1 퐼(푌푖(푡) ≥ 푠, 퐴푖 = 푎), and the total at-risk proportionis 푅(푡, 푠) = 푅1(푡, 푠) + 푅0(푡, 푠). The standardized Fleming-Harrington class weighted log-rank test statistic (WLRT) stopped at
time 푡 is given by
휌,훾 (푡) =
∑푛
푖=1 ∫ 푡0 푤휌,훾 (푠)[퐴푖 − 푅1(푡,푠)푅(푡,푠) ]푁푖(푡, 푑푠)√∑푛
푖=1 ∫ 푡0 푤2휌,훾 (푠)푅1(푡,푠)푅0(푡,푠)푅(푡,푠)2 푁푖(푡, 푑푠)
, (2)
with a Fleming-Harrington weight푤휌,훾 (푠) = 푆(푠−)휌{1−푆(푠−)}훾 . We denote the numerator of (2) as 퐺휌,훾 (푡), and its asymptotic
variance 푉 (퐺휌,훾 (푡)) can be estimated via the denominator:
푉̂ (퐺휌,훾 (푡)) =
푛∑
푖=1
푡
∫
0
푤2휌,훾 (푠)
푅1(푡, 푠)푅0(푡, 푠)
푅(푡, 푠)2
푁푖(푡, 푑푠). (3)
Thus formula in (2) can also be written into and should satisfy the following equation 휌,훾 (푡) = 퐺휌,훾 (푡)∕
√
푉̂ (퐺휌,훾 (푡)) =
퐺휌,훾 (푡)∕
√
푉 (퐺휌,훾 (푡)) + 표푝(1).
Modifying the two parameters 휌 and 훾 can adjust the shape of the weights, and thus the focus of the detection. For instance,
휌 = 훾 = 0, the test statistic is reduced to a standard log-rank test (SLRT), which provides best power in the presence of PH;
while 휌 = 0 and 훾 = 1, it emphasizes more on late separations and thus provides better power for delayed effect.
Sample size calculation for a confirmatory clinical trial is based on the predefined null and alternative hypotheses (denoted
by 퐻0 and 퐻1). Letting 푧훼 and 푧1−훽 be critical values of standard normal distribution, and Δ the effective difference between
two arms (e.g. the constant log hazard ratio under PH), The required number of events for SLRT has a closed-form expression7
given by
푑 =
(푧훼 + 푧1−훽)2
푝(1 − 푝)Δ2
. (4)
The sample size computation for WLRT, however, was established following a stochastic process approach suggested by
Lakatos12 and Hasegawa10. Suppose 푏 is the number of intervals at each time unit (month), and 퐽 (푡) = 푓푙표표푟(푏푡) is the total
number of time intervals at an equal length [푠0 = 0, 푠1, 푠2,… , 푠퐽 = 푡], where 푡 represents a stopping time as aforementioned.
There follows the mean estimator 퐸̃푠푡표,퐻 (퐺휌,훾 (푡)) and variance/information estimator of the numerator in (2):
퐸̃푠푡표,퐻 (퐺휌,훾 (푡)) =
퐽 (푡)−1∑
푗=0
퐷∗푗,퐻 (푡)푤
∗
휌,훾 (푗)
[ 휙푗휃푗
1 + 휙푗휃푗
−
휙푗
1 + 휙푗
]
,퐻 = 퐻1,퐻0; (5)
푉̃푠푡표,퐻 (퐺휌,훾 (푡)) =
퐽 (푡)−1∑
푗=0
퐷∗푗,횯(푡)푤
∗2
휌,훾 (푗)
휙푗
(1 + 휙푗)2
; (6)
where,
푅∗1(0) = 푝, 푅
∗
0(0) = 1 − 푝,푤
∗
휌,훾 (푗) = 푆(푠푗)
휌[1 − 푆(푠푗)]훾 ,
푅∗푎(푗 + 1) = 푅
∗
푎(푗)
[
1 − ℎ∗푎(푠푗)
1
푏
− 퐼(푠푗>휏−푅)
푏(휏−푠푖)
]
, ℎ∗푎(푠푗) =
푓푎(푠푗 )
푆푎(푠푗 )
, 푎 = 0, 1,
휃∗푗 =
ℎ1(푠푗 )
ℎ0(푠푗 )
, 휙∗푗 =
푅∗1(푠푗 )
푅∗0(푠푗 )
, 퐷∗푗,퐻 (푡) =
[{
ℎ∗0(푠푗)푅
∗
0(푗) + ℎ
∗
1(푠푗)푅
∗
1(푗)
} 1
푏
]
min( 푡
푅
, 1).
(7)
Note that we set퐻 = 퐻1 for the alternative hypothesis and퐻 = 퐻0 the null hypothesis in formulas (5)-(7). It is also expected to
see that 퐸̃푠푡표,퐻0(퐺휌,훾 (푡)) = 0 in that 휃푗 = 1 for ∀푗. In this report, we name the mean and variance in (5)-(6) be “predicted” valuessince none of the observation data are used here. Moreover, we use accent tilde to distinguish them from those estimated from
observed events in (3). The difference between the prediction and estimation methods merely depends on whether the observed
event times are used in the computation. Henceforth, prediction is usually used for early trial design purpose, but estimation is
more often implemented when part of the data have been collected. The marginal survival function is the weighted average of
two treatment arms: 푆(푠) = (1 − 푝)푆0(푠) + 푝푆1(푠). In contrast to the proposal by Hasegawa10, there is an extra multiplicative
term min( 푡
푅
, 1) for the formulation of 퐷∗푗,횯1(푡) in (7) to account for a special case that 푡 < 푅, i.e., stopping before the end ofaccrual period.
Lakatos12 suggested that 휌,훾 (푡) follows an asymptotically normal distribution with unit variance and mean approximated by
휇̃휌,훾,퐻 (푡) =
퐸̃푠푡표,퐻 (퐺휌,훾 (푡))√
푉̃푠푡표,퐻 (퐺휌,훾 (푡))
. (8)
Fixing 푡 = 휏 for tests at the end of the study, the required sample sizes in terms of the total number of subjects (푛) and observed
events (푑) are
푛 =
(
푧훼+푧1−훽
휇̃휌,훾,퐻1 (휏)
)2
푑 = 푛퐷∗퐻1(휏),
(9)
where 퐷∗퐻1(휏) =
∑퐽 (휏)−1
푗=0 퐷
∗
푗,퐻1
(휏) approximates the probability of observing an event from each subject under퐻1.
2.3 Maxcombo test
In practice, the true survival curves or the hazard ratio between the treatment arms are usually unknown; moreover, the existence
of delayed treatment effect and its severity can hardly be predicted in advance. To that end, Lee9 proposed a versatile max-
combo test, taking the maximum of a combo of different WLRTs to cover various scenarios: PH case, NPH cases with early,
middle and late effects, etc. The general form of a maxcombo test is
푚푎푥(푡) = max (휌1,훾1(푡),휌2,훾2(푡),… ,휌퐾 ,훾퐾 (푡)) , (10)
where 휌푘,훾푘(푡) is one of the퐾 different Fleming-Harrington family WLRTs. Boundary calculation for a maxcombo test statisticis equivalent to finding the boundary value 푔(휏) at the end of the study (time 휏) such that the type one error (훼) is under control:
푃 (푚푎푥(휏) < 푔(휏) ∣ 퐻0) = 1 − 훼. (11)
According to Lee13,(푡) = [휌1,훾1(푡),… ,휌퐾 ,훾퐾 (푡)]′ is (asymptotically) multivariate normal distributed withmean 0 and variance1, and the correlation for two different WLRTs with 푘1 ≠ 푘2 is given by
퐶표푟(휌푘1 ,훾푘1 (푡),휌푘2 ,훾푘2 (푡)) =
퐶표푣(퐺휌푘1 ,훾푘1 (푡), 퐺휌푘2 ,훾푘2 (푡))√
푉 (퐺휌푘1 ,훾푘1 (푡))푉 (퐺휌푘2 ,훾푘2 (푡))
. (12)
The variances can be obtained through either the data-driven estimation 푉̂ (퐺휌,훾 (푡)) from (3) or the stochastic prediction
푉̃푠푡표(퐺휌,훾 (푡)) from (6). In a similar vein, covariance can be obtained following either prediction or estimation via the equation
given by
퐶표푣(퐺휌푘1 ,훾푘1 (푡), 퐺휌푘2 ,훾푘2 (푡)) = 푉
{
퐺 휌푘1 +휌푘2
2 ,
훾푘1 +훾푘2
2
(푡)
}
. (13)
Alternatively, for the (piece-wise) exponential distributions, one can derive close-form expressions for their mean, variance,
and covariance values according to their exact distribution functions, for which we denote as “exact prediction”, and indexing
with an “exa” for distinction. Please check the exactly predicted variances (푉̃푒푥푎) and covariance (퐶̃표푣푒푥푎) for a piece-wise expo-
nential survival distribution in Appendix B. The exact prediction method can largely alleviate the computational burden, though
the closed-form solutions may not exist for complex survival curves. To that end, one might refer to numerical approximation
by transforming the integration to a summation over many small intervals, which is quite similar to the proposed stochastic
prediction method.
Under 퐻1, the asymptotic mean for each WLRT can be approximated through (8), and thus the mean vector 흁̃(푡) =
[휇̃휌1,훾1,퐻1(푡),… , 휇̃휌퐾 ,훾퐾 ,퐻1(푡)]
′. The approximate asymptotic distribution of the test statistics(푡) is multivariate normal withmean√
푛흁̃(푡) and the covariance/correlation matrix can be obtained via the prediction methods proposed for the boundary calculation
in (12). Note that we do not consider using the estimation approach for sample size calculation, since sample size calculation
is usually decided before starting the trial in group sequential designs. The sample size will be obtained through solving the
function below so that the type II error equals 훽:
푃 (푚푎푥(휏) < 푔(휏) ∣ 퐻1) = 훽. (14)
2.4 Group Sequential Design for Maxcombo tests
Practitioners often employ interim analyses or group sequential designs in clinical trials. They will save time and budgets by
stopping a trial early when there is sufficient statistical evidence to terminate the study: futility, unexpected side effects, and
significant treatment effect. There were extensive discussions about introducing maxcombo tests to group sequential design on
the FDA workshop at Duke-Margolis Health Policy Center in 201814. Plenty of simulations have shown that maxcombo could
potentially improve the robustness when NPH exists. However, there are mainly two problems that hinder the implementation
of GS-MC: 1) how to compute the boundaries at each stage to control the type I error; 2) how to compute the sample size.
Simulations can solve both two problems, but the computational burden could be considerable. To avoid the tedious simulations,
we propose a design procedure that can control the type I and accurately predicted the required sample size by approximating
the asymptotic distribution of all the test statistics across different stopping points.
3 PROPOSED SOLUTIONS
3.1 Correlation matrix approximation
The correlation matrix of the test statistics requires 3 different types of correlation values. The first type is the within-stage
correlation between different tests, e.g. 퐶표푟(휌푘1 ,훾푘1 (푡),휌푘2 ,훾푘2 (푡)), which can be computed following equation (12). The secondtype is within-test correlation between two stopping time points, or 퐶표푟(휌,훾 (푡푚1),휌,훾 (푡푚2)) for 0 < 푡푚1 < 푡푚2 ≤ 휏 and 푚1 < 푚2,computed from
퐶표푟(휌,훾 (푡푚1),휌,훾 (푡푚2)) =
√
푉 (퐺휌,훾 (푡푚1))
푉 (퐺휌,훾 (푡푚2))
. (15)
The information fraction 퐼퐹휌,훾 (푡푚1 , 푡푚2) = 푉 (퐺휌,훾 (푡푚1))∕푉 (퐺휌,훾 (푡푚2)) under the square root of (15) was used to decide stop-ping times in group sequential designs15. Note that (15) asymptotically holds only under퐻0, when the independent increment
property 퐶표푣(퐺휌,훾 (푡푚1), 퐺휌,훾 (푡푚2)) = 푉 (퐺휌,훾 (푡푚1)) is asymptotically true16. Although not strictly satisfied under 퐻1, the inde-pendent increment property and thus the equation (15) almost hold numerically when the difference between two treatment arms
are not considerable (under the so-called “local alternatives") or when the events are not too frequent, according to Example 1
in Luo et al11 and our simulations in Section 4. Note that the variance value for both within-test and within-stage correlations
can be obtained via both prediction and estimation approaches.
The third type includes correlations across different time points and test types. We propose a simple calculation based on the
first two types of correlations by introducing the Theorem 1, which is also proved in Appendix A.
Theorem 1. If random variables 푋1, 푋2 and 푋3 have mean 0, variance 1, satisfying 푋3 = 휙푋2 +푀 , 푀 ⟂ (푋1, 푋2) with
퐸(푀) = 0, and 휙 is a constant value, then the equality 푐표푟(푋1, 푋3) = 푐표푟(푋1, 푋2)푐표푟(푋2, 푋3) holds.
In particular, let 푋1 = 휌푘1 ,훾푘1 (푡푚1) − 퐸[휌푘1 ,훾푘1 (푡푚1)] and 푋2 = 휌푘2 ,훾푘2 (푡푚1) − 퐸[휌푘2 ,훾푘2 (푡푚1)], then it holds that 푋3 =휌푘2 ,훾푘2 (푡푚2)−퐸[휌푘2 ,훾푘2 (푡푚2)] = 휙푋2+푀 , where휙 =
√
퐼퐹휌푘2 ,훾푘2 (푡푚1 , 푡푚2) and푀 = [퐺휌푘2 ,훾푘2 (푡푚2)−퐺휌푘2 ,훾푘2 (푡푚1)−퐸{퐺휌푘2 ,훾푘2 (푡푚2)−
퐺휌푘2 ,훾푘2 (푡푚1)}]∕
√
푉 (퐺휌푘2 ,훾푘2 (푡푚2)). Note that under the퐻0 we have 퐸(퐺휌,훾 (푡)) = 0. Similar to the comments for the second-type
correlation,푀 ⟂ (푋1, 푋2) is asymptotically correct following the asymptotic independent increment property16 under the퐻0,
and only approximately true under 퐻1 when the difference between two arms and the event hazards are limited within some
practical range. In the Section 4, we conducted extensive simulations to explore how well the this approximation is in various
scenarios and in the presence of multiple assumption violations (Table 3, Web Tables 3-6). Following Theorem 1, we have the
third-type correlation given by
퐶표푟(휌푘1 ,훾푘1 (푡푚1),휌푘2 ,훾푘2 (푡푚2)) =
퐶표푟(휌푘1 ,훾푘1 (푡푚1), 퐺휌푘2 ,훾푘2 (푡푚1))퐶표푟(휌푘2 ,훾푘2 (푡푚1),휌푘2 ,훾푘2 (푡푚2)). (16)
With all the 3 different types of correlations calculated using either distribution-based prediction or data-driven estimation, the
two sets of correlation matrices are obtained under퐻0 and퐻1.
3.2 Type I error: boundaries
We introduce boundary vector 품 = [푔(푡1),… , 푔(푡푀 )]′ for M stages including a final stage and푀 − 1 interim stages. To control
the type I error at each stage, we employ a monotone increasing error spending function 훼(휈) with 휈 ∈ [0, 1], 훼(0) = 0 and
훼(1) = 훼 17. Suppose that wemonitor the information fractions at times 0 = 푡0 < 푡1 <⋯ < 푡푀 = 휏 satisfying 퐼퐹휌푘,훾푘(푡푚, 휏) = 휈푚,where 0 = 휈0 < 휈1 < ⋯ < 휈푀 = 1 are pre-defined, and 푤휌푘,훾푘 indicates the 푘푡ℎ WLRTs in the combo to monitor stoppingtimes. Error spending funcitonn 훼(푣) controls type I error spent at each stage via step-wise equations for stage 푚 = 1,… ,푀 ,
푃 (푚푎푥(푡푗) ≤ 푔(푡푗), 푗 = 1,… , 푚 − 1,푚푎푥(푡푚) > 푔(푡푚) ∣ 퐻0) = 훼(휈푚) − 훼(휈푚−1). (17)
The boundary values 품 can be obtained via solving the multivariate normal distribution with mean 0, and variance matrix 횺0
with all the diagonal entries to be 1, and off-diagonal correlation entries computed following Subsection 3.1.
3.3 Power: sample size
The sample size calculation is based on the asymptotic distribution of the multivariate normal distribution under 퐻1. With all
the boundaries decided in Subsection 3.2, the sample sizes (푛) can be solved such that we have
푃 (푚푎푥(푡푚) ≤ 푔(푡푚), 푚 = 1,… ,푀 ∣ 퐻1) = 훽. (18)
In group sequential trials, sample size calculation usually precedes the trial. we will obtain the sample size according
to predicted mean √푛[흁̃(푡1)′,… , 흁̃(푡푀 )′]′ and variance matrix 횺̃1 of  = [(푡1)′,(푡2)′,… ,(푡푀 )′]′, where (푡푚)′ =
[휌1,훾1(푡푚),… ,휌퐾 ,훾퐾 (푡푚)]. The required event count is 푑 = 푛퐷∗퐻1(휏).
3.4 A complete design
The complete design is summarized in Figure 1. First, one will need to decide the plan by defining the hypotheses퐻0 and퐻1,
their survival functions,퐾WLRTswithin the combo,푀−1 interim stages, and the corresponding stopping rule 휈푚. The stopping
rule is dependent on the information fraction of one of the WLRTs in the combo, i.e., stopping at 퐼퐹훾푘,휌푘(푡푚) = 휈푚 for 푚푡ℎ testif the previous 푚 − 1 stages fail to reject퐻0. For instance, if using surrogate information fraction15, it would base on the event
counts. The correlation matrices can be obtained using either the prediction approach or the estimation approach. Prediction can
be done using the stochastic method and the exact method, whereby the former would apply to all kinds of survival functions and
also consider the changing at-risk proportion of treatment group, while the latter treats this proportion a constant value (denoted
to be p) in the formulas given in Appendix B. The estimation approach is entirely data-driven, following equations (3) and (13).
The stopping times are predicted according to the predicted information fractions, and thus we obtain the resulting distribu-
tions of the multivariate test statistics under both hypotheses. As follows, the boundaries at each stage and sample size can be
predicted as well. Moreover, once we start the trial, data are collected, and the correlation matrix can be estimated following (3).
Therefore, instead of using the predicted correlations, one can also estimate the correlation matrices for boundary and sample
size calculation, in order to ensure that the type I error can still be controlled when the assumed survival distributions, censoring
process, or accrual procedure are violated in practice.
4 SIMULATION STUDIES
We used the two-piece exponential provided in Appendix B as an example to demonstrate and compare the performance of our
proposed approaches. The event times from the control arm is following an exponential distribution with rate 휆 = 푙표푔(2)∕6
(median survival: 6 months), while the event times from the treatment arm were generated following a two-piece exponential
with its hazard changing from 휆 to 휃휆 at after 휖 = 2 months of follow-up. When 휃 = 1, the two-piece exponential is reduced to
an exponential distribution identical to the control group. To strictly follow the piece-wise exponential distribution suggested in
(1) with 푄 = 2, we let 횯0 = {1, 1} for 퐻0 and 횯1 = {1, 휃} for 퐻1, where 휃 ∈ (0, 1) and 휖1 = 휖, which is equivalent to (B4).
Simulations under different scenarios were carried out to evaluate the proposed methods for a reasonable range of post-delay
treatment effects (휃 ∈ [0.5, 0.7]). To begin, we generated data following uniform accrual within time interval [0, 푅], where
푅 = 14; and with a probability 푝 = 0.5, the subjects were randomly assigned to the treatment arm. All the studies were expected
to end at 휏 = 18. We included two log-rank test statistics for a maxcombo test 푚푎푥(푡) = max(0,0(푡),0,1(푡)), and one interim
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FIGURE 1A flow-chart to describe the procedure of the proposed simulation-free GS-MC design. The superscript “*” indicates
that the correlation matrices can be predicted using both the stochastic and exact approaches, while the mean (휇̃) is predicted
using stochastic approach to enjoy a more precise approximation as the at-risk proportions change by time. The “analysis” stage
is when we conducted the maxcombo tests under various scenarios with or without assumption violations, and the output of this
step is the decision to reject or accept퐻0, which are summarized as type I error and power in simulations. The arrows between
the blocks indicate directions of the information flow.
stopping stage. Thus we have푀 = 2 and 퐾 = 2. Note that 0,1(푡) tends to be more powerful than 0,0(푡) in the presence of a
delayed treatment effect. In practice, however, the existence of such a delayed effect is generally unknown. Moreover, its severity
(in terms of 휃 and 휖) can hardly be predicted, thus incorporating more WLRTs can potentially provide better robustness. In the
following simulations, we only focus on one-sided tests, with their type I error controlled at level 훼 = 0.25 and sample size
targeting power 1 − 훽 = 0.9, respectively. For each simulation study, we generated 200,000 datasets for type I error evaluation,
and 50,000 for power estimation.
The stopping times were decided according to the information fraction of the SLRT 0,0, or namely the surrogate information
fraction in Hasegawa15. We stopped for an interim analysis at 푡푖푛푡 when 0.6푑 events were observed, and terminated the study for
a final analysis at 푡푓푖푛 when 푑 events were observed. In other words, we let 휈1 = 0.6 and 휈2 = 1. Note that 푑 is the total number
of events we need and will be predicted once the stopping times are predicted. In particular, the stopping times (푡푖푛푡 and 푡푓푖푛)
can be decided by solving 퐷∗퐻 (̃푡푖푛푡) = 0.6퐷∗퐻1(휏) and 퐷∗퐻 (̃푡푓푖푛) = 퐷∗퐻1(휏), with 퐻 = 퐻0 when the null hypothesis is true, and
퐻 = 퐻1 otherwise. Or in other more general cases when monitoring any WLRT with respect to its information fraction, one
would predict the stopping times by solving 푉̃푠푡표,퐻 (퐺휌,훾 (̃푡푖푛푡)) = 0.6푉̃푠푡표,퐻1(퐺휌,훾 (휏)) and 푉̃푠푡표,퐻 (퐺휌,훾 (̃푡푓푖푛)) = 푉̃푠푡표,퐻1(퐺휌,훾 (휏)). Note
that the two sets of stopping times can differ under different hypotheses, and consequently the predicted correlation matrices
(횺̃0 and 횺̃1) are different too. The mean of the test statistics under퐻0 is ퟎ4, but is [흁̃(̃푡푖푛푡)′, 흁̃(̃푡푓푖푛)′]′ under퐻1. We obtained the
predicted boundaries 품̃ and sample sizes 푑 or 푛 based on the predicted mean and correlation matrices. We can also predict the
stopping times and subsequently the correlation matrices using the exact-prediction method given in Appendix B. Alternatively,
the boundaries 푔̂(푡) can be updated according to the data by calculating the estimated correlation matrix 횺̂0 following (3) and
(13), which is expected to be more accurate than the prediction methods in the presence of violations in the distributional
assumptions of the survival, censoring and accrual processes. We used R package mvtnorm18 for the boundary calculation.
Since it is seed-dependent, we each time generated 5 replicates, and keep the median of them as output value. All the prediction
and estimation methods proposed in this report have been established in an R package on Github (lilywang1988/GSMC).
First, we tested various post-delay hazard ratios with only administrative censoring and correctly specified survival functions,
in consistence with the assumptions given in Hasegawa10. All results were summarized in Table 1 , where GS-WLRT denotes
group sequential design with aWLRT 0,1(푡), GS-SLRT denotes group sequential design with SLRT 0,0(푡), and GS-MC denotes
group sequential design with a maxcombo test of 0,1(푡) and 0,0(푡). Note that since all the tests were in group sequential designs,
we eliminated prefix ‘GS” in the summary tables. In GS-MC, we consider the naive method with boundaries that are identical
to the other two univariate tests GS-WLRT and GS-SLRT, which are stopped according to the observed events (namely, the
surrogate information fraction of SLRT according to Hasegawa15). To produce fair comparisons, we computed sample sizes for
GS-MC using proposed prediction methods (the stochastic and exact methods), whose results turned out to be identical. The
boundaries for the other three GS-MC methods were computed from the prediction (stochastic or exact), and the estimation
approaches as well. As expected, in the presence of a delayed treatment effect, GS-SLRT provided a controlled type I error
for the correct boundary specification under 퐻0, but the powers were much lower than the rest because it did not consider
the delayed treatment effect well. On the other hand, GS-WLRT provides a much higher power than GS-SLRT, but the type I
error (0.0259 − 0.0268) was obviously above the nominal 0.025, which is because the surrogate information fraction did not
reflect the true correlation between the two stopping times for WLRT, or in other words, the boundaries for GS-SLRT were not
appropriate for GS-WLRT. To that end, it was suggested to monitor the true information fractions of WLRT instead of using the
surrogate information fraction by Hasegawa15. The naive GS-MC appeared to enjoy a higher power than WLRT, but its type
I error (≈ 0.04) was also not controlled under the nominal 0.025. This is another example that the event count ratio (surrogate
information fraction) did not reflect the correlation between the two maxcombo tests at the interim and final stages.
There did not seem to exist much difference comparing the performance among the proposed approaches, though the estima-
tion approach had slightly better power than the two predicted methods with their type I error controlled similarly. The stochastic
prediction does not limit its survival function to piece-wise exponential distributions. All the three proposed approaches per-
formed much better than the naive method in controlling the type I error. By increasing the post-delay separation up to 휃 = 0.5,
the type I error increased slightly above 0.025, and the power decreased. There could be mainly two explanations: 1) the accrual
sample size decreased from 푛 = 927 (푑 = 597) to 푛 = 274 (푑 = 166) when the post-delay hazard ratio was decreased from
휃 = 0.7 to 휃 = 0.5, thus the tails of the distribution for the test statistic became heavier; 2) the increasing treatment effect caused
a more serious violation of the independent increment assumption, and thus damaged the approximation accuracy.
Then we tested different special cases with some of the assumptions, e.g., uniform accrual, administrative censoring, correctly
specified survival hazards, and delayed time being violated. For violation I, the accrual is no longer uniform with a monthly
accrual rate 푛∕14 subjects per month, but instead is 푛∕70, 2푛∕70, 3푛∕70, 4푛∕70 for the first 4 months, and then 6푛∕70 for rest
10 months. In the presence of violation I, still there are 푛 subjects enrolled by the end of the accrual period 푅 = 14, but the
accrual rate is increasing for the first four months before getting stabilized at a constant rate. For violation II, censoring is not
limited to a shared administrative censoring but can differ between treatment arms. In particular, we generated censoring time
following exponential distributions with a yearly censoring proportion 20% for the treatment group and 10% for the control
group. For violation III, the true median survival time for the control group is 12 months, other than the presumed six months.
For violation IV, the separation occurs at six months after the enrollment, instead of the predefined two months. The results
under various post-delay treatment hazard ratios with violations I and II (I&II) were summarized in Table 2, and those with an
additional violation III (I&II&III) or violation IV (I&II&IV) were in Web Tables 1-2. Their corresponding correlation matrices
can be found in Web Tables 3-6, and the subset results of 휃 = 0.6 in Table 3.
According to Table 2, it turned out that all the three proposed approaches were quite robust to misspecifications of the accrual
process and the censoring mechanism (violations I&II). The average stopping times (푡푖푛푡, 푡푓푖푛) were larger than those from
Table 1, to collect enough events (information) in front of the additional censoring. The detection power was even better, possibly
due to a long waiting time before ending the study enabled us to collect more events after the start of the separation. Similar to the
TABLE 1 The rejection probabilities under the null hypothesis denoted by퐻0 (type I error) and under the alternative hypothesis
퐻1 (power) when censoring, accrual, and survival functions are correctly specified. Prefixes “GS” standing for “group-
sequential” are eliminated here for simplicity. Sample sizes were decided according to GS-MC, and both prediction approaches
provided identical sample sizes. Note that among the proposed GS-MC methods, the predicted powers are 0.3692, 0.3630,
0.3543 for 휃 ∈ {0.7, 0.6, 0.5} at the interim stage respectively, and all are 0.9 with two stages combined.
휃 = 0.7 휃 = 0.6 휃 = 0.5
Test Stage 퐻0 퐻1 퐻0 퐻1 퐻0 퐻1
WLRT combined 0.0260 0.9143 0.0262 0.9140 0.0269 0.9137
interim 0.0051 0.4082 0.0052 0.4039 0.0055 0.3983
SLRT combined 0.0251 0.8272 0.0252 0.8206 0.0246 0.8103
interim 0.0051 0.2487 0.0049 0.2355 0.0050 0.2283
MC (naive) combined 0.0384 0.9279 0.0388 0.9273 0.0390 0.9258
interim 0.0082 0.4346 0.0082 0.4282 0.0085 0.4213
MC (pred-sto) combined 0.0251 0.8970 0.0253 0.8962 0.0255 0.8948
interim 0.0050 0.3691 0.0051 0.3620 0.0054 0.3579
MC (pred-exa) combined 0.0252 0.8972 0.0253 0.8963 0.0255 0.8950
interim 0.0050 0.3693 0.0051 0.3621 0.0054 0.3582
MC (est) combined 0.0252 0.8972 0.0253 0.8966 0.0255 0.8952
interim 0.0050 0.3693 0.0051 0.3622 0.0054 0.3581
size n= 927 d=597 n=475 d=297 n=274 d=166
results without any violations in Table 1, the estimation approach has slightly better power than the two prediction methods, with
all their type I error controlled similarly. Note that since the subjects were enrolled slower than those with uniform enrollment
in Table 1 at the early stage, the power was generally lower at the interim stage.
Other additional violations were considered in the Web Tables 1-2. When there existed another violation that the event hazard
휆 = log(2)∕12 was wrongly specified to be 휆 = log(2)∕6 (I&II&III), the waiting time before observing enough events would
be longer than that without violation III in Tables 1-2, and thus producing a higher power for delayed separation according to
Web Table 5. Or when the delayed effect time 휖 = 6 was misspecified to be 휖 = 2 in addition to the violations in censoring and
accrual (I&II&IV), the power would become much lower than the expected value according to Web Table 6, since the required
sample sizes to achieve the nominal power was largely underestimated. Among all the combinations of violations we tested, the
type I error was not affected much, while the power was obviously affected depending on the degree of violations of the model
assumptions.
To scrutinize whether the correlation matrices were accurately approximated and how they were affected by the viola-
tions, we compared correlations computed using the prediction and estimation approaches with or without violations I&II for
휃 = 0.6 in Table 3, and all other cases in Web Tables 3-6. The mean correlations of the simulated datasets were treated as
gold standards. When there was no assumption violation, none of the correlations had more than 5% difference from the gold
standard (Table 3 and Web Table 3). Only the predicted 푐̃표푟(0,1(푡푖푛푡),0,1(푡푓푖푛)) and 푐̃표푟(0,0(푡푖푛푡),0,1(푡푓푖푛)) were over 5%
different from the gold standard correlations under 퐻1 (Table 3 and Web Table 4), possibly because the violations in censor-
ing and accrual mechanisms affect the prediction of the stopping times, the predicted correlations of 퐺0,1(푡) are not correctly
reflecting the true correlations between stopping times. Note that 푐표푟(0,0(푡푖푛푡),0,1(푡푓푖푛)) is approximated by the product of
푐표푟(0,1(푡푖푛푡),0,1(푡푓푖푛)) and 푐표푟(0,0(푡푖푛푡),0,1(푡푖푛푡)) following (16). In the presence of violations I&II&III, the predicted corre-
lations for 푐표푟(0,1(푡푖푛푡),0,1(푡푓푖푛)) and 푐표푟(0,0(푡푖푛푡),0,1(푡푓푖푛)) would suffer from a severe bias with over 25% difference from
the gold standard values. Misspecification of the delayed time, on the contrary, did not impact the correlation matrices much.
The estimation method provides the most accurate correlation approximations, and the correlations predicted via the stochastic
method is slightly more accurate than those via the exact prediction method. The type I error, however, seems not being affected
much by the correlation matrices. We checked the boundaries predicted and estimated under different violation combinations
and found that their changes were extremely small (< 0.003 in magnitudes), implying that slight bias in the correlations did not
exert considerable influence on the boundary calculation under퐻0.
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TABLE 2 The rejection probabilities under the null hypothesis denoted by퐻0 (type I error) and under the alternative hypothesis
퐻1 (power) when censoring and accrual are misspecified. Prefixes “GS” standing for “group-sequential” are eliminated here
for simplicity.
휃 = 0.7 휃 = 0.6 휃 = 0.5
Test Stage 퐻0 퐻1 퐻0 퐻1 퐻0 퐻1
WLRT combined 0.0259 0.9172 0.0261 0.9159 0.0268 0.9135
interim 0.0052 0.3747 0.0053 0.3663 0.0052 0.3569
SLRT combined 0.0248 0.8325 0.0248 0.8224 0.0250 0.8128
interim 0.0053 0.2156 0.0051 0.2002 0.0051 0.1917
MC (naive) combined 0.0379 0.9293 0.0383 0.9279 0.0391 0.9252
interim 0.0085 0.3996 0.0084 0.3883 0.0084 0.3782
MC (pred-sto) combined 0.0246 0.9010 0.0247 0.8976 0.0256 0.8953
interim 0.0052 0.3339 0.0052 0.3255 0.0051 0.3145
MC (pred-exa) combined 0.0246 0.9012 0.0248 0.8976 0.0256 0.8954
interim 0.0053 0.3342 0.0052 0.3258 0.0051 0.3147
MC (est) combined 0.0246 0.9012 0.0247 0.8979 0.0256 0.8956
interim 0.0052 0.3335 0.0051 0.3252 0.0051 0.3141
TABLE 3 Comparison of the correlations computed using different methods: the correlations calculated directly from the
simulated samples (푐표푟), the predicted values using either stochastic process (푐̃표푟푠푡표) or exact distribution (푐̃표푟푒푥푎), and the data-
driven estimation (푐̂표푟). The sample correlations were treated as the gold standard for a fair comparison on the other methods.
In comparison with the gold-standard mean, correlations with difference 5−10%were made italic, and > 10%were made bold.
No violation Violations I&II
Correlation pair 퐻0 퐻1 퐻0 퐻10,1(푡푖푛푡) 푐표푟 0.8329 0.8348 0.8261 0.8263
&0,0(푡푖푛푡) 푐̃표푟푠푡표 − 푐표푟 -0.0029 -0.0038 0.0040 0.0047
푐̃표푟푒푥푎 − 푐표푟 -0.0009 -0.0015 0.0059 0.0070
푐̂표푟 − 푐표푟 -0.0017 -0.0027 -0.0007 0.00060,1(푡푓푖푛) 푐표푟 0.8452 0.8516 0.8482 0.8529
&0,0(푡푓푖푛) 푐̃표푟푠푡표 − 푐표푟 0.0107 0.0145 0.0176 0.0230
푐̃표푟푒푥푎 − 푐표푟 0.0120 0.0162 0.0188 0.0247
푐̂표푟 − 푐표푟 -0.0010 -0.0018 -0.0008 -0.00140,0(푡푖푛푡) 푐표푟 0.7766 0.7791 0.7763 0.7797
&0,0(푡푓푖푛) 푐̃표푟푠푡표 − 푐표푟 -0.0037 -0.0033 -0.0035 -0.0039
푐̃표푟푒푥푎 − 푐표푟 -0.0046 -0.0016 -0.0043 -0.0021
푐̂표푟 − 푐표푟 -0.0020 -0.0045 -0.0017 -0.00510,1(푡푖푛푡) 푐표푟 0.6457 0.6267 0.6158 0.5884
&0,1(푡푓푖푛) 푐̃표푟푠푡표 − 푐표푟 -0.0068 -0.0074 0.0232 0.0309
푐̃표푟푒푥푎 − 푐표푟 -0.0068 -0.0052 0.0232 0.0331
푐̂표푟 − 푐표푟 -0.0012 -0.0077 0.0000 -0.00820,1(푡푖푛푡) 푐표푟 0.6475 0.6493 0.6414 0.6454
&0,0(푡푓푖푛) 푐̃표푟푠푡표 − 푐표푟 -0.0060 -0.0046 0.0002 -0.0008
푐̃표푟푒푥푎 − 푐표푟 -0.0052 -0.0014 0.0009 0.0024
푐̂표푟 − 푐표푟 -0.0037 -0.0047 -0.0020 -0.00490,0(푡푖푛푡) 푐표푟 0.5375 0.5262 0.5093 0.4887
&0,1(푡푓푖푛) 푐̃표푟푠푡표 − 푐표푟 -0.0071 -0.0115 0.0211 0.0260
푐̃표푟푒푥푎 − 푐표푟 -0.0059 -0.0083 0.0223 0.0292
푐̂표푟 − 푐표푟 -0.0018 -0.0111 -0.0011 -0.0089
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FIGURE 2 Sample sizes needed to achieve the required power 훽 = 0.9 for the group sequential design in the presence of
different delayed effect times (휖). The required number of subjects (푛) and events (푑) were plotted against the delay-effect times
휖 in [0, 3.5].
To demonstrate the advantage of using maxcombo in group sequential designs, we computed the required sample sizes fol-
lowing (18) in comparison with all the single tests from the combo. The results were presented in Figure 2 in terms of patient
numbers (푛) and event counts (푑). The settings were consistent with those of simulations for Table 1: no assumption violation,
fixing post-delay hazard ratio to be 휃 = 0.6 and varying the delayed time 휖 from 0 to 3.5. We plotted three curves in Figure 2:
the GS-MC test of 푚푎푥(푡) = max(0,0(푡),0,1(푡)), GS-WLRT (0,1(푡)) and GS-SLRT (0,0(푡)). According to Figure 2, when the
delay-time is close to 0 (< 0.75), 0,0(푡) requires the smallest sample size, while 0,1(푡) requires the biggest, consistent to the
case that PH is dominant. When the waiting time before treatment effect 휖 is long (> 1.15), 0,1(푡) becomes more powerful and
thus requires a smaller sample size. Interestingly, in the intermediate state, when 휖 ∈ [0.75, 1.15], the maxcombo test requires
smaller sample sizes than the other two. It implies that the sample size needed from a maxcombo test is always nearly the most
powerful one among all the tests in the combo. Therefore, we conclude that employing a maxcombo test in a group sequential
design tends to reduce the sample size and largely improve the testing robustness.
5 DISCUSSION
In this report, we proposed a general framework for a group sequential design with maxcombo tests or GS-MC in short. The
proposed design is completely simulation-free, can effectively control the type I error and find the required sample size to achieve
the nominal ideal power under퐻1. We have developed two prediction methods that are based on the assumed distributions under
the two hypotheses (퐻0 and 퐻1), and one data-driven estimation method. We demonstrated in our simulation studies that the
proposed approaches displayed strong robustness towards various violations of assumptions related to survival, censoring, and
accrual processes.
Note that among the prediction methods, the stochastic approach can adapt to various survival functions. One can also extend
the use of the exact prediction by repeating the derivations of the formulas in Appendix B. Most often, the stochastic prediction
method and the exact predictionmethod exhibit similar performance (depending on the number of intervals 푏), though the former
is usually more flexible but also more computationally expensive than the latter.
When we were preparing the manuscript, we notice another group also developed a correlation matrix approximation method,
which shares some similar features to our proposal19. Their proposed method directly calculates all the correlations using the
independent increment properties, but ours computes the third type of correlations based on the first two types. It can be shown
that the two methods are numerically equivalent for the correlation matrix computation under 퐻0. Another major difference
between the two methods lies in the fact that their approach is not entirely simulation-free, since their sample size calculation
needs simulations.
We have established all the functions used in the proposed design in an R package on GitHub (lilywang1988/GSMC). Note
that the proposed design can accommodate a regular maxcombo test without interim analysis by setting푀 = 1. Although in
this report, we restrict our scope to group sequential designs with sample sizes decided in advance, the proposed approach can
be extended to adaptive designs, whereby sample sizes are adjusted based on the observed data.
SUPPORTING INFORMATION
The following supporting information is available as part of the online article:
Web Table 1 The rejection probabilities under the null hypothesis denoted by 퐻0 (type I error) and under the alternative
hypothesis퐻1 (power) when the censoring, accrual and event hazards are misspecified.
Web Table 2 The rejection probabilities under the null hypothesis denoted by 퐻0 (type I error) and under the alternative
hypothesis퐻1 (power) when the censoring, accrual and delayed time are misspecified.
Web Table 3 Comparison of the correlations computed using different methods without violation in accrual (I), censoring (II),
survival functions (III) or delayed time (IV).
Web Table 4 Comparison of the correlations computed using different methods with violations I (accrual) and II (censoring).
Web Table 5 Comparison of the correlations computed using different methods with violations I (accrual), II (censoring), and
III(event rate).
Web Table 6 Comparison of the correlations computed using different methods with violations I (accrual), II (censoring), and
IV(delayed time).
APPENDIX
A PROOF FOR THEOREM 1
Proof. This is equivalent to prove
퐸[푋1푋2]퐸[푋2푋3] = 퐸[푋1푋3]퐸[푋22 ] (A1)
Since 푋3 = 푋2 +푀 and푀 ⟂ (푋1, 푋2), we have the left-hand side (LHS) of (A1) to be
퐿퐻푆 = 퐸[푋1푋2]퐸[푋2(휙푋2 +푀)]
= 휙퐸(푋1푋2)퐸(푋22 ).
(A2)
The right-hand side (RHS) of (A1) is
푅퐻푆 = 퐸[푋1(휙푋2 +푀)]퐸[푋22 ]
= 휙퐸(푋1푋2)퐸(푋22 ).
(A3)
Thus the equality in (A1) holds.
B EXACT PREDICTIONS
For simplicity, we demonstrated the exact prediction for a simple case following the survival functions given in Fine20 and
Hasegawa10, where the control group is following an exponential distribution and the treatment group is following a a two-piece
exponential with delayed effect 휃 at 휖:
푆0(푠) = exp(−휆푠), 푆1(푠) =
{
푒푥푝(−휆푠) 푓표푟 푠 ≤ 휖,
푐 exp(−휃휆푠) 푓표푟 푠 > 휖; (B4)
푓0(푠) = 휆 exp(−휆푠), 푓1(푠) =
{
휆 exp(−휆푠) = 휆푆1(푠) 푓표푟 푠 ≤ 휖,
휃휆푐 exp(−휃휆푠) = 휃휆푆1(푠) 푓표푟 푠 > 휖,
(B5)
Note that in (B4) and (B5), we have 푐 = exp(−(1 − 휃)휆휖) and 휃 as the effective post-delay hazard ratio 휃 ∈ (0, 1). If 휖 = 0, (B4)
and (B5) are reduced to a PH case.
According to15, the predicted variance or information is
푉̃푒푥푎(퐺휌,훾 (푡)) = 푛푝(1 − 푝)
⎡⎢⎢⎣
푡
∫
0
min( 푡 − 푠
푅
, 1)푆(푠)2휌(1 − 푆(푠))2훾푓 (푠)푑푠
⎤⎥⎥⎦ , (B6)
Under the null hypothesis, 푆(푡) = 푆0(푡) and 푓 (푡) = 푓0(푡), but under the alternative hypothesis, 푆(푡) = 푝푆1(푡) + (1 − 푝)푆0(푡) and
푓 (푡) = 푝푆1(푡) + (1− 푝)푆0(푡), where p is the treatment assignment probability. The major difference between 푉̃푒푥푎 and 푉̃푠푡표 is that
the at-risk proportion for the treatment group is fixed to be 푝 in 푉̃푒푥푎(퐺휌,훾 (푡)).
We introduce some utility functions 푢푣(), 푢() and 푣():
푣(푡, 휖, 푘, 휆) = 퐼(휖 ≤ 푡 − 푅) ∫ 푡0 min( 푡−푥푅 , 1) exp(−푘휆푥)휆퐼(푥 ≤ 휖)푑푥
= 1
푘
{1 − exp(−푘휆휖)}
(B7)
푢(푡, 휖, 푘, 휆) = 퐼(휖 > 푡 − 푅) ∫ 푡0 min( 푡−푥푅 , 1) exp(−푘휆푥)휆퐼(푥 ≤ 휖)푑푥
= 1
푘
[
1 − exp(−푘휆(푡 − 푅)+)
]
+ 푅∧푡
푘푅
exp(−푘휆(푡 − 푅)+)
− (푡−휖)
+
푘푅
exp(−푘휆휖 ∧ 푡) + 1
푘2푅휆
[
exp(−푘휆휖 ∧ 푡) − exp(−푘휆(푡 − 푅)+)
]
,
(B8)
where (푎)+ = max(푎, 0) and 푎 ∧ 푏 = min(푎, 푏).
푢푣(푡, 휖, 푘, 휆) = 퐼(휖 > 푡 − 푅)푢(푡, 휖, 푘, 휆) + 퐼(휖 ≤ 푡 − 푅)푣(푡, 휖, 푘, 휆) (B9)
Based on the basic utility functions, there are some other advanced utility functions, ℎ1(), ℎ0() and ℎ̃(), for the variance/in-
formation prediction under the alternative hypothesis:
ℎ1(푡, 푘1, 푘2) = − ∫ 푡0 min( 푡−푥푅 , 1)푆1(푥)푘1푆0(푥)푘2푑푆1(푥)
= 푢푣(푡, 휖, 푘1 + 푘2 + 1, 휆)+
푐푘1+1휃
{
푢(푡, 푡, 휃(푘1 + 1) + 푘2, 휆) − 푢푣(푡, 휖, 휃(푘1 + 1) + 푘2, 휆)
} (B10)
ℎ0(푡, 푘1, 푘2) = − ∫ 푡0 min( 푡−푥푅 , 1)푆1(푥)푘1푆0(푥)푘2푑푆0(푥)
= 푢푣(푡̃, 푘1 + 푘2 + 1, 휆)+
푐푘1
{
푢(푡, 푡, 휃푘1 + 푘2 + 1, 휆) − 푢푣(푡, 휖, 휃푘1 + 푘2 + 1, 휆)
} (B11)
ℎ̃(푡, 푘) = − ∫ 푡0 min( 푡−푥푅 , 1)푆푘(푥)푑푆(푥)
= − ∫ 푡0 min( 푡−푥푅 , 1)∑푘푖=0 (푘푖)푝푖(1 − 푝)푘−푖푆 푖1(푥)푆푘−푖0 (푥)푑[푝푆1(푥) + (1 − 푝)푆0(푥)]
=
∑푘
푖=0
(푘
푖
)
푝푖+1(1 − 푝)푘−푖ℎ1(푡, 푖, 푘 − 푖) +
∑푘
푖=0
(푘
푖
)
푝푖(1 − 푝)푘−푖+1ℎ0(푡, 푖, 푘 − 푖)
(B12)
The the predicted variance under the null hypothesis using the exact assumed distributions is
푉̃푒푥푎(퐺휌,훾 (푡)) = 푛푝(1 − 푝) ×
⎧⎪⎪⎨⎪⎪⎩
푢(푡, 푡, 1, 휆) 푓표푟 휌 = 0, 훾 = 0;
푢(푡, 푡, 3, 휆) 푓표푟 휌 = 1, 훾 = 0;
푢(푡, 푡, 1, 휆) + 푢(푡, 푡, 3, 휆) − 2푢(푡, 푡, 2, 휆) 푓표푟 휌 = 0, 훾 = 1;
푢(푡, 푡, 3, 휆) + 푢(푡, 푡, 5, 휆) − 2푢(푡, 푡, 4, 휆) 푓표푟 휌 = 1, 훾 = 1.
(B13)
The the predicted variance under the alternative hypothesis using the exact assumed distributions is
푉̃푒푥푎(퐺휌,훾 (푡)) = 푛푝(1 − 푝) ×
⎧⎪⎪⎨⎪⎪⎩
ℎ̃(푡, 0) 푓표푟 휌 = 0, 훾 = 0;
ℎ̃(푡, 2) 푓표푟 휌 = 1, 훾 = 0;
ℎ̃(푡, 0) + ℎ̃(푡, 2) − 2ℎ̃(푡, 1) 푓표푟 휌 = 0, 훾 = 1;
ℎ̃(푡, 2) + ℎ̃(푡, 4) − 2ℎ̃(푡, 3) 푓표푟 휌 = 1, 훾 = 1.
(B14)
The predicted covariance values 퐶̃표푣푒푥푎(휌1,훾1(푡),휌2,훾2(푡)) can be obtained following the similar strategy using 푢() and ℎ̃()functions, by changing the squared weight of B6 to 푆(푡)휌1+휌2(1 − 푆(푡))훾1+훾2 .
The formulas above can be easily extended to accommodate survival functions that are piece-wise exponential distributions
with more than two pieces.
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